Immix Biopharma announced the pricing of an underwritten registered offering of 11,363,637 common shares at $11 per share, with gross proceeds expected to reach $125 million before underwriting discounts, commissions and offering expenses. The offering is expected to close on or about Sept. 30, 2026, subject to customary conditions. Immix plans to use the net proceeds for development of NXC-201, working capital and general corporate purposes. J.P. Morgan is the sole book-running manager, and the offering includes new and existing institutional investors including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments L.P. and Wellington Management. NXC-201 is a BCMA-targeted CAR-T therapy being evaluated in the NEXICART-2 study for relapsed/refractory AL Amyloidosis. The company said the candidate has received Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the U.S. Food and Drug Administration, as well as Orphan Drug Designation from the FDA and the European Medicines Agency.